Endometrial receptivity defects during IVF cycles with and without letrozole

Paul B. Miller, Brent A Parnell, Greta Bushnell, Nicholas Tallman, David A. Forstein, H. Lee Higdon, Jo Kitawaki, Bruce A. Lessey

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background Our aim was to study ways to improve IVF success rates in women with suspected endometrial receptivity defects.Methods We conducted a retrospective cohort study examining the effect of letrozole (aromatase inhibitor) on integrin expression as a marker of endometrial receptivity. We compared IVF outcomes in 97 infertile women who had undergone ανβ3 integrin assessment by immunohistochemistry in mid-luteal endometrial biopsies. Of 79 women undergoing standard IVF, 29 (36.7) lacked normal integrin expression. Eighteen other women with low integrin were studied after receiving letrozole during early IVF stimulation. An independent set of ανβ3 integrin-negative patients (n 15) who had undergone repeat endometrial biopsy for integrin testing while taking letrozole were re-evaluated. Results Clinical pregnancy and delivery rates were higher in women with normal ανβ3 integrin expression compared with those who were integrin negative [20/50 (40) versus 4/29 (13.8); P 0.02 and 19/50 (38) versus 2/29 (7); P < 0.01, respectively]. In 18 women who received letrozole early in IVF, 11 conceived (61.1; P < 0.001) compared with integrin-negative patients who did not receive letrozole. In integrin-negative women who were rebiopsied on letrozole, 66.7 reverted to normal integrin expression. Positive endometrial aromatase immunostaining using a polyclonal antibody was a common finding in infertile patients compared with controls. Conclusions Lack of endometrial ανβ3 integrin expression is associated with a poor prognosis for IVF that might be improved with letrozole co-treatment. Prospective studies are needed to confirm and extend these findings but the data suggest that aromatase expression may contribute to implantation failure in some women.

Original languageEnglish (US)
Pages (from-to)881-888
Number of pages8
JournalHuman Reproduction
Volume27
Issue number3
DOIs
StatePublished - Jan 1 2012

Fingerprint

letrozole
Integrins
Aromatase

Keywords

  • IVF/ICSI outcome
  • endometrial receptivity
  • endometriosis
  • female infertility
  • implantation

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Miller, P. B., Parnell, B. A., Bushnell, G., Tallman, N., Forstein, D. A., Higdon, H. L., ... Lessey, B. A. (2012). Endometrial receptivity defects during IVF cycles with and without letrozole. Human Reproduction, 27(3), 881-888. https://doi.org/10.1093/humrep/der452

Endometrial receptivity defects during IVF cycles with and without letrozole. / Miller, Paul B.; Parnell, Brent A; Bushnell, Greta; Tallman, Nicholas; Forstein, David A.; Higdon, H. Lee; Kitawaki, Jo; Lessey, Bruce A.

In: Human Reproduction, Vol. 27, No. 3, 01.01.2012, p. 881-888.

Research output: Contribution to journalArticle

Miller, PB, Parnell, BA, Bushnell, G, Tallman, N, Forstein, DA, Higdon, HL, Kitawaki, J & Lessey, BA 2012, 'Endometrial receptivity defects during IVF cycles with and without letrozole', Human Reproduction, vol. 27, no. 3, pp. 881-888. https://doi.org/10.1093/humrep/der452
Miller PB, Parnell BA, Bushnell G, Tallman N, Forstein DA, Higdon HL et al. Endometrial receptivity defects during IVF cycles with and without letrozole. Human Reproduction. 2012 Jan 1;27(3):881-888. https://doi.org/10.1093/humrep/der452
Miller, Paul B. ; Parnell, Brent A ; Bushnell, Greta ; Tallman, Nicholas ; Forstein, David A. ; Higdon, H. Lee ; Kitawaki, Jo ; Lessey, Bruce A. / Endometrial receptivity defects during IVF cycles with and without letrozole. In: Human Reproduction. 2012 ; Vol. 27, No. 3. pp. 881-888.
@article{f2156e6bc9d94745a6c5fc7f407780be,
title = "Endometrial receptivity defects during IVF cycles with and without letrozole",
abstract = "Background Our aim was to study ways to improve IVF success rates in women with suspected endometrial receptivity defects.Methods We conducted a retrospective cohort study examining the effect of letrozole (aromatase inhibitor) on integrin expression as a marker of endometrial receptivity. We compared IVF outcomes in 97 infertile women who had undergone ανβ3 integrin assessment by immunohistochemistry in mid-luteal endometrial biopsies. Of 79 women undergoing standard IVF, 29 (36.7) lacked normal integrin expression. Eighteen other women with low integrin were studied after receiving letrozole during early IVF stimulation. An independent set of ανβ3 integrin-negative patients (n 15) who had undergone repeat endometrial biopsy for integrin testing while taking letrozole were re-evaluated. Results Clinical pregnancy and delivery rates were higher in women with normal ανβ3 integrin expression compared with those who were integrin negative [20/50 (40) versus 4/29 (13.8); P 0.02 and 19/50 (38) versus 2/29 (7); P < 0.01, respectively]. In 18 women who received letrozole early in IVF, 11 conceived (61.1; P < 0.001) compared with integrin-negative patients who did not receive letrozole. In integrin-negative women who were rebiopsied on letrozole, 66.7 reverted to normal integrin expression. Positive endometrial aromatase immunostaining using a polyclonal antibody was a common finding in infertile patients compared with controls. Conclusions Lack of endometrial ανβ3 integrin expression is associated with a poor prognosis for IVF that might be improved with letrozole co-treatment. Prospective studies are needed to confirm and extend these findings but the data suggest that aromatase expression may contribute to implantation failure in some women.",
keywords = "IVF/ICSI outcome, endometrial receptivity, endometriosis, female infertility, implantation",
author = "Miller, {Paul B.} and Parnell, {Brent A} and Greta Bushnell and Nicholas Tallman and Forstein, {David A.} and Higdon, {H. Lee} and Jo Kitawaki and Lessey, {Bruce A.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1093/humrep/der452",
language = "English (US)",
volume = "27",
pages = "881--888",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Endometrial receptivity defects during IVF cycles with and without letrozole

AU - Miller, Paul B.

AU - Parnell, Brent A

AU - Bushnell, Greta

AU - Tallman, Nicholas

AU - Forstein, David A.

AU - Higdon, H. Lee

AU - Kitawaki, Jo

AU - Lessey, Bruce A.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background Our aim was to study ways to improve IVF success rates in women with suspected endometrial receptivity defects.Methods We conducted a retrospective cohort study examining the effect of letrozole (aromatase inhibitor) on integrin expression as a marker of endometrial receptivity. We compared IVF outcomes in 97 infertile women who had undergone ανβ3 integrin assessment by immunohistochemistry in mid-luteal endometrial biopsies. Of 79 women undergoing standard IVF, 29 (36.7) lacked normal integrin expression. Eighteen other women with low integrin were studied after receiving letrozole during early IVF stimulation. An independent set of ανβ3 integrin-negative patients (n 15) who had undergone repeat endometrial biopsy for integrin testing while taking letrozole were re-evaluated. Results Clinical pregnancy and delivery rates were higher in women with normal ανβ3 integrin expression compared with those who were integrin negative [20/50 (40) versus 4/29 (13.8); P 0.02 and 19/50 (38) versus 2/29 (7); P < 0.01, respectively]. In 18 women who received letrozole early in IVF, 11 conceived (61.1; P < 0.001) compared with integrin-negative patients who did not receive letrozole. In integrin-negative women who were rebiopsied on letrozole, 66.7 reverted to normal integrin expression. Positive endometrial aromatase immunostaining using a polyclonal antibody was a common finding in infertile patients compared with controls. Conclusions Lack of endometrial ανβ3 integrin expression is associated with a poor prognosis for IVF that might be improved with letrozole co-treatment. Prospective studies are needed to confirm and extend these findings but the data suggest that aromatase expression may contribute to implantation failure in some women.

AB - Background Our aim was to study ways to improve IVF success rates in women with suspected endometrial receptivity defects.Methods We conducted a retrospective cohort study examining the effect of letrozole (aromatase inhibitor) on integrin expression as a marker of endometrial receptivity. We compared IVF outcomes in 97 infertile women who had undergone ανβ3 integrin assessment by immunohistochemistry in mid-luteal endometrial biopsies. Of 79 women undergoing standard IVF, 29 (36.7) lacked normal integrin expression. Eighteen other women with low integrin were studied after receiving letrozole during early IVF stimulation. An independent set of ανβ3 integrin-negative patients (n 15) who had undergone repeat endometrial biopsy for integrin testing while taking letrozole were re-evaluated. Results Clinical pregnancy and delivery rates were higher in women with normal ανβ3 integrin expression compared with those who were integrin negative [20/50 (40) versus 4/29 (13.8); P 0.02 and 19/50 (38) versus 2/29 (7); P < 0.01, respectively]. In 18 women who received letrozole early in IVF, 11 conceived (61.1; P < 0.001) compared with integrin-negative patients who did not receive letrozole. In integrin-negative women who were rebiopsied on letrozole, 66.7 reverted to normal integrin expression. Positive endometrial aromatase immunostaining using a polyclonal antibody was a common finding in infertile patients compared with controls. Conclusions Lack of endometrial ανβ3 integrin expression is associated with a poor prognosis for IVF that might be improved with letrozole co-treatment. Prospective studies are needed to confirm and extend these findings but the data suggest that aromatase expression may contribute to implantation failure in some women.

KW - IVF/ICSI outcome

KW - endometrial receptivity

KW - endometriosis

KW - female infertility

KW - implantation

UR - http://www.scopus.com/inward/record.url?scp=84857206666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857206666&partnerID=8YFLogxK

U2 - 10.1093/humrep/der452

DO - 10.1093/humrep/der452

M3 - Article

C2 - 22246449

AN - SCOPUS:84857206666

VL - 27

SP - 881

EP - 888

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 3

ER -